Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Vistagen Therapeutics (VTGN) Equity Ratio (2016 - 2025)

Vistagen Therapeutics (VTGN) has disclosed Equity Ratio for 13 consecutive years, with 0.78 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 10.94% to 0.78 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.78 through Dec 2025, down 10.94% year-over-year, with the annual reading at 0.83 for FY2025, 9.7% down from the prior year.
  • Equity Ratio hit 0.78 in Q4 2025 for Vistagen Therapeutics, down from 0.82 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.94 in Q4 2023 to a low of 0.46 in Q2 2023.
  • Historically, Equity Ratio has averaged 0.81 across 5 years, with a median of 0.83 in 2021.
  • Biggest five-year swings in Equity Ratio: skyrocketed 285.28% in 2021 and later crashed 41.9% in 2023.
  • Year by year, Equity Ratio stood at 0.88 in 2021, then dropped by 21.22% to 0.7 in 2022, then soared by 35.16% to 0.94 in 2023, then decreased by 6.57% to 0.88 in 2024, then decreased by 10.94% to 0.78 in 2025.
  • Business Quant data shows Equity Ratio for VTGN at 0.78 in Q4 2025, 0.82 in Q3 2025, and 0.82 in Q2 2025.